RESUMO
BACKGROUND: This study aimed to explore the effects of recombinant human thrombopoietin (rhTPO) on platelet recovery in decitabine, cytarabine, aclarubicin, and G-CSF (DCAG)-treated patients with intermediate-high-risk myelodysplastic syndrome/hypo proliferative acute myeloid leukemia. METHODS: Recruited patients were at a ratio of 1:1 into 2 groups: the rhTPO group (DCAGâ +â rhTPO) and control group (DCAG). The primary endpoint was the time for platelets to recover toâ ≥â 20â ×â 109/L. The secondary endpoints were the time for platelets to recover toâ ≥â 30â ×â 109/L andâ ≥â 50â ×â 109/L, overall survival (OS), and progression-free survival (PFS). RESULTS: The time required for platelet recovery toâ ≥â 20â ×â 109/L, ≥30â ×â 109/L, andâ ≥â 50â ×â 109/L in the rhTPO group was significantly shorter (6.5â ±â 2.2 vs 8.4â ±â 3.1 days, 9.0â ±â 2.7 vs 12.2â ±â 3.9 days, 12.4â ±â 4.7 vs 15.5â ±â 9.3 days, respectively; all Pâ <â .05 vs controls). The amount of platelet transfusion in the rhTPO group was smaller (4.4â ±â 3.1 vs 6.1â ±â 4.0 U, Pâ =â .047 vs controls). The bleeding score was lower (Pâ =â .045 vs controls). The OS and PFS were significantly different (Pâ =â .009 and Pâ =â .004). The multivariable analysis showed that age, karyotype, and time for PLT recovery toâ ≥â 20â ×â 109/L were independently associated with OS. Adverse events were similar. CONCLUSIONS: This study suggests that rhTPO leads to a faster platelet recovery after DCAG treatment, reduces the risk of bleeding, reduces the number of platelet transfusions, and prolongs the OS and PFS.
Assuntos
Leucemia Mieloide Aguda , Síndromes Mielodisplásicas , Humanos , Trombopoetina/uso terapêutico , Plaquetas , Proteínas Recombinantes/uso terapêutico , Síndromes Mielodisplásicas/tratamento farmacológico , Leucemia Mieloide Aguda/tratamento farmacológicoRESUMO
Although Indoleamine 2,3-dioxygenase (IDO), tryptophan-2,3-dioxygenase (TDO), and aryl hydrocarbon receptor (AHR) are involved in cancer immune escape, their prognostic impact on diffuse large B-cell lymphoma (DLBCL) is unknown.To examine the prognostic impact of IDO, TDO, and AHR on patients with DLBCL.This was a retrospective study on treatment-naïve patients with newly diagnosed DLBCL at the Henan Province People's Hospital between 01/2012 and 06/2015. Patients with inflammatory reactive lymph nodes were included as controls. All cases were reviewed by 2 pathologists. IDO, TDO, and AHR positivity was determined through immunochemistry. Survival was examined using the Kaplan-Meier method and multivariable Cox analyses.The positive expression of TDO (50.0% vs 16.7%, Pâ=â.005) and AHR (60.0% vs 8.3%, Pâ<â.001) were higher in DLBCL than in inflammatory control. The overall survival of IDO, TDO, and AHR positive expression in DLBCL patients was 34.6, 26.7, and 32.2 months, respectively, which is significantly shorter than that of the corresponding negative patients (49.0 months, Pâ=â.04; 58.2 months, Pâ<â.001; 58.0 months, Pâ<â.001; respectively). The multivariable analysis showed that TDO expression and Ann-Arbor stage were independently associated with PFS (TDO: HRâ=â8.347, 95%CI: 2.992-23.289, Pâ<â.001; stage: HRâ=â2.729, 95%CI: 1.571-4.739, Pâ<â.001) and OS (TDO: HRâ=â9.953, 95%CI: 3.228-30.686, Pâ<â.001; stage: HRâ=â2.681, 95%CI: 1.524-4.719, Pâ=â.001) in DLBCL patients.Overexpression of IDO, TDO, and AHR is associated with poor survival of patients with DLBCL and could be involved in the immune escape of cancer cells. Further studies are necessary to determine whether these proteins can be targeted by treatment regimens.